105 related articles for article (PubMed ID: 27466518)
1. Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Lee BN; Jung S; Darvin ME; Eucker J; Kühnhardt D; Sehouli J; Chekerov R; Patzelt A; Fuss H; Yu RX; Lademann J
Anticancer Res; 2016 Aug; 36(8):4089-93. PubMed ID: 27466518
[TBL] [Abstract][Full Text] [Related]
2. Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
Fuss H; Lademann J; Jung S
Anticancer Res; 2018 Sep; 38(9):5283-5288. PubMed ID: 30194179
[TBL] [Abstract][Full Text] [Related]
3. Prevention of palmoplantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin (Caelyx®).
Jung S; Sehouli J; Chekerov R; Kluschke F; Patzelt A; Fuss H; Knorr F; Lademann J
Support Care Cancer; 2017 Nov; 25(11):3545-3549. PubMed ID: 28653108
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes.
Akoglu G
Indian J Pharmacol; 2014; 46(2):225-7. PubMed ID: 24741199
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.
Harris CS; Wang D; Carulli A
J Oncol Pharm Pract; 2014 Feb; 20(1):73-80. PubMed ID: 23478198
[TBL] [Abstract][Full Text] [Related]
6. Influence of mechanical stress on palmoplantar erythrodysesthesia--a case report.
Jung S; Sehouli J; Patzelt A; Lademann J
Oncol Res Treat; 2015; 38(1-2):42-4. PubMed ID: 25765506
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced erythrodysesthesia of the breast.
Alcalde-Castro J; Soto-Perez-de-Celis E; Reyes-Gutiérrez E; Orozco-Topete R; León-Rodríguez E; Chávarri-Guerra Y
Breast J; 2018 Sep; 24(5):828-830. PubMed ID: 29738105
[No Abstract] [Full Text] [Related]
8. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.
Eich D; Scharffetter-Kochanek K; Eich HT; Tantcheva-Poor I; Krieg T
Am J Clin Oncol; 2002 Dec; 25(6):599-602. PubMed ID: 12478008
[TBL] [Abstract][Full Text] [Related]
9. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Risum S; Langer SW
Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
[TBL] [Abstract][Full Text] [Related]
10. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy.
Lademann J; Martschick A; Kluschke F; Richter H; Fluhr JW; Patzelt A; Jung S; Chekerov R; Darvin ME; Haas N; Sterry W; Zastrow L; Sehouli J
Skin Pharmacol Physiol; 2014; 27(2):66-70. PubMed ID: 23969763
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
Ajgal Z; Chapuis N; Emile G; Cessot A; Tigaud JM; Huillard O; Boudou-Rouquette P; Fontenay M; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1033-9. PubMed ID: 26420236
[TBL] [Abstract][Full Text] [Related]
12. Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane.
Corazza M; Minghetti S; Borghi A; Virgili A; Ballardini P
Int J Dermatol; 2014 Mar; 53(3):e180-2. PubMed ID: 23621794
[No Abstract] [Full Text] [Related]
13. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
[TBL] [Abstract][Full Text] [Related]
14. Palmoplantar erythrodysesthesia-like skin symptoms in patients under various chemotherapeutics: preventive and therapeutic options.
Lademann J; Röwert-Huber HJ; Haas N; Kluschke F; Patzelt A; Zastrow L; Lange-Asschenfeldt B; Jung S; Sterry W; Sehouli J
Skin Pharmacol Physiol; 2014; 27(5):229-33. PubMed ID: 24802288
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous hand and foot toxicity associated with cancer chemotherapy.
Childress J; Lokich J
Am J Clin Oncol; 2003 Oct; 26(5):435-6. PubMed ID: 14528066
[No Abstract] [Full Text] [Related]
16. Docetaxel induced severe palmar plantar erythrodysesthesia.
Kharmoum S; Errihani H
Pan Afr Med J; 2018; 30():70. PubMed ID: 30344854
[No Abstract] [Full Text] [Related]
17. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of comparison of CAF regimen and TP regimen in treatment of advanced breast cancer].
Lin XG; Xie DR; Yao HR; Li ZH; Jiang ZM; Liu TH
Ai Zheng; 2003 Apr; 22(4):411-4. PubMed ID: 12704001
[TBL] [Abstract][Full Text] [Related]
20. Palmar-plantar erythrodysesthesia.
Gupta A; Mehta A; Khanna S
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359464
[No Abstract] [Full Text] [Related]
[Next] [New Search]
